Best overall response per International Working Group 2007 criteria assessed by the investigator
| . | Favezelimab plus pembrolizumab (MK-4280-003 cohort 2) (N = 27) . | Pembrolizumab monotherapy (KEYNOTE-087) (N = 81) . |
|---|---|---|
| Objective response rate (95% CI), % | 37 (15-51) | 2 (0-6) |
| Best response, n (%) | ||
| Complete response | 3 (11) | 0 |
| Partial response | 7 (26) | 2 (2) |
| Stable disease | 11 (41) | 23 (28) |
| Progressive disease | 6 (22) | 56 (69) |
| . | Favezelimab plus pembrolizumab (MK-4280-003 cohort 2) (N = 27) . | Pembrolizumab monotherapy (KEYNOTE-087) (N = 81) . |
|---|---|---|
| Objective response rate (95% CI), % | 37 (15-51) | 2 (0-6) |
| Best response, n (%) | ||
| Complete response | 3 (11) | 0 |
| Partial response | 7 (26) | 2 (2) |
| Stable disease | 11 (41) | 23 (28) |
| Progressive disease | 6 (22) | 56 (69) |